Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions for maintenance of electrolyte balance and normal cellular function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolarity.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion. The typical adult dose is 20-40 mEq of potassium per day, administered as an infusion rate not exceeding 10 mEq/hour or 0.5 mEq/kg/hour. Concentration is 0.11% KCl (1.46 mEq/L) provided in 0.9% NaCl.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable; potassium is a physiologic ion with rapid equilibration; serum levels reflect total body stores and renal function; in anephric patients, half-life extends to 30-50 hours.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal (>90%) as potassium ions; negligible biliary/fecal elimination under normal conditions.
Category C
Category A/B
Electrolyte
Electrolyte